Technical Analysis for PSNL - Personalis, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
C | 1.63 | 1.24% | 0.02 |
PSNL closed up 1.24 percent on Monday, March 18, 2024, on 54 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. It was able to bounce off of its 200 day moving average, an important long-term support line.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
200 DMA Support | Bullish | 0.00% | |
NR7 | Range Contraction | 0.00% | |
NR7-2 | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Crossed Above 200 DMA | Bullish | 1.24% | |
Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 1.24% | |
NR7 | Range Contraction | 1.24% | |
Inside Day | Range Contraction | 1.24% | |
Wide Bands | Range Expansion | 1.24% |
Alert | Time |
---|---|
Possible NR7 | about 10 hours ago |
Down 1% | about 10 hours ago |
Fell Below 200 DMA | about 11 hours ago |
60 Minute Opening Range Breakdown | about 12 hours ago |
200 DMA Support | about 13 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/01/2024
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. The company also provides a complementary liquid biopsy assay that analyzes various human genes versus. It serves approximately 45 biopharmaceutical customers, including a range of pharmaceutical companies. The company was founded in 2011 and is headquartered in Menlo Park, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Pharmaceutical Biology Telehealth Telemedicine Genomics Medical Genetics Molecular Diagnostics Applied Genetics Cancer Therapies Analysis Services Biopsy Cancer Therapy Data Analysis Services Treating Cancer Oncogenomics
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Pharmaceutical Biology Telehealth Telemedicine Genomics Medical Genetics Molecular Diagnostics Applied Genetics Cancer Therapies Analysis Services Biopsy Cancer Therapy Data Analysis Services Treating Cancer Oncogenomics
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 3.26 |
52 Week Low | 0.8912 |
Average Volume | 427,480 |
200-Day Moving Average | 1.60 |
50-Day Moving Average | 1.53 |
20-Day Moving Average | 1.56 |
10-Day Moving Average | 1.67 |
Average True Range | 0.15 |
RSI (14) | 54.34 |
ADX | 27.1 |
+DI | 19.25 |
-DI | 13.65 |
Chandelier Exit (Long, 3 ATRs) | 1.35 |
Chandelier Exit (Short, 3 ATRs) | 1.64 |
Upper Bollinger Bands | 1.91 |
Lower Bollinger Band | 1.21 |
Percent B (%b) | 0.6 |
BandWidth | 44.32 |
MACD Line | 0.06 |
MACD Signal Line | 0.06 |
MACD Histogram | 0.0012 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.73 | ||||
Resistance 3 (R3) | 1.73 | 1.70 | 1.72 | ||
Resistance 2 (R2) | 1.70 | 1.67 | 1.70 | 1.71 | |
Resistance 1 (R1) | 1.66 | 1.65 | 1.68 | 1.66 | 1.71 |
Pivot Point | 1.63 | 1.63 | 1.63 | 1.63 | 1.63 |
Support 1 (S1) | 1.59 | 1.60 | 1.61 | 1.60 | 1.55 |
Support 2 (S2) | 1.56 | 1.58 | 1.56 | 1.55 | |
Support 3 (S3) | 1.52 | 1.56 | 1.54 | ||
Support 4 (S4) | 1.53 |